Pharmaceutical Technology's In the Lab eNewsletter
Shimadzu’s Imagereveal MS mass spectrometry imaging data analysis software can analyze large sets of data or simultaneously analyze multiple sets of data.
The Imagereveal MS mass spectrometry imaging data analysis software from Shimadzu simplifies the data analysis process by enabling data to be analyzed from a variety of perspectives without requiring extra time or effort. The software is suited to analyze large sets of data or simultaneously analyze multiple sets of data.
Mass spectrometry imaging is used to analyze two-dimensional images that show the distribution of substances measured with a mass spectrometer. The company reports that in recent years, technical advancements in spatial resolution and mass accuracy have generated excessively large amounts of data that inhibit data analysis.
The software resolves these issues by offering functionalities that search massive amounts of mass spectrometry imaging data for the information required, which can dramatically improve research efficiency, as stated by the company. The software includes six types of functionality for data analysis with different availabilities of that functionality depending on the license selected by the user. A data converter can also be used to analyze data measured by a mass spectrometer not manufactured by the company.
Shimadzu will exhibit the software at the Japan Analytical Instruments Manufacturers (JASIS) convention, from Sept. 5–7, 2018 at the Makuhari Messe International Exhibition Hall in Chiba, Japan.
Source: Shimadzu
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.